Salarius Pharmaceuticals Inc SLRX

NAS: SLRX | ISIN: US79400X1072 14/11/2024

1,380 USD (-2,13%)

(-2,13%) 14/11/2024

Grafiek Salarius Pharmaceuticals Inc

Grafiek Salarius Pharmaceuticals Inc

1 dag1d -2,13%
1 week1w -8,00%
1 maand1m -9,21%
3 maanden3m -31,34%
6 maanden6m 201,31%
1 jaar1j 86,74%
5 jaar5j -61,40%

Salarius Pharmaceuticals Inc in het nieuws

Toon enkel gratis nieuws

18 maart 2021 · Salarius Pharmaceuticals Reports Business Highlights with Fourth Quarter and Full-Year 2020 Financial Results · Persbericht

11 maart 2021 · Salarius Pharmaceuticals to Report Fourth Quarter and Full Year 2020 Financial Results · Persbericht

8 maart 2021 · Salarius Announces Closing of $23 Million Underwritten Public Offering of Common Stock Following Full Exercise of Over-Allotment Option · Persbericht

3 maart 2021 · Salarius Announces Proposed Public Offering of Common Stock · Persbericht

22 februari 2021 · Salarius Pharmaceuticals to Present at the Diamond Equity Research Emerging Growth Invitational Virtual Conference · Persbericht

16 februari 2021 · Salarius Pharmaceuticals to Present at BIO CEO & Investor Digital Conference · Persbericht

21 januari 2021 · Salarius Pharmaceuticals Regains Compliance with Nasdaq Minimum Bid Price Listing Requirement · Persbericht

15 januari 2021 · Salarius Pharmaceuticals Announces Dr. Daniela Santiesteban to Participate in Panel Discussion on Targeted Cancer Therapies During Virtual NobleCon17 Investor Conference · Persbericht

13 januari 2021 · Salarius Pharmaceuticals Receives Second Installment of $1.7 Million in Payments from the Cancer Prevention and Research Institute of Texas · Persbericht

Profiel Salarius Pharmaceuticals Inc

Commerciële diensten

Diverse commerciële diensten

Fabricage van farmaceutische preparaten

Farmaceutische producten: Andere

Gezondheidstechnologie

Website: www.flex-pharma.com

Hoofdzetel: Houston, Texas Verenigde Staten

CEO: David Arthur

Werknemers: 14

Mijn selecties

Je selectie is nog leeg.

Voeg nu effecten toe